STARTS NOW! Rebel Edge 🏴☠️1pm line up: U.S. crude oil prices are dropping due to weak demand from China and expected higher U.S. production after the election. WTI is notably lower, part of a wider commodity slump. Stocks $TSLA $COIN $ABBV $HOOD Sports Detroit's kicker makes 58… https://t.co/mZXNAn84q8 https://t.co/HBCDrov0gz
Cerevel gains as AbbVie says it expects deal to close soon (update)
SeekingAlpha
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie
SeekingAlpha
AbbVie cuts 2024 profit forecast on R&D expenses https://t.co/WTkmzTGw1V https://t.co/EOEaZXsEJq
@Reuters
Cerevel Therapeutics drops amid report on FTC review of AbbVie deal
SeekingAlpha
AbbVie buys bowel disease drug developer Celsius for $250M
SeekingAlpha
Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal
SeekingAlpha
AbbVie says FDA approves Skyrizi for ulcerative colitis
MarketWatch
Cerevel Therapeutics gains after AbbVie says making good progress with FTC
SeekingAlpha
$COR $UNH $ABBV $ACAD $NVS $REGN | After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora publicly acknowledged the breach on February 27 after filing a notice with government regulators.
Despite… https://t.co/8qToXmkbOW https://t.co/h8ZQs2luQB
@Benzinga
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC
Landos shares rocket 170% on AbbVie takeover deal
SeekingAlpha
FDA grants full approval to AbbVie/ImmunoGen drug Elahere
SeekingAlpha
AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals
SeekingAlpha
AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira
MarketWatch
Cerevel, AbbVie get FTC Second Requests for more merger info
SeekingAlpha
AbbVie revises Q1 earnings outlook as ImmunoGen deal closes
SeekingAlpha
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
MarketWatch
ImmunoGen spikes as HSR waiting period for AbbVie deal expires
SeekingAlpha
AbbVie – Cerevel deal reportedly followed unusual options trading
SeekingAlpha
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say https://t.co/eJNLf96jCm https://t.co/CVmzjEAVVM
@Reuters
AbbVie – Cerevel M&A deal lifts Reviva, Karuna
SeekingAlpha
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion - CNBC
CNBC
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
MarketWatch
Cerevel Therapeutics jumps after Abbvie agrees to $8.7B takeover (update)
SeekingAlpha
$ABBV $CERE | AbbVie Nears Roughly $8B For Drug Developer Cerevel -Reuters https://t.co/xdE6a1KvVM
@Benzinga
ImmunoGen downgraded on Wall Street expecting AbbVie deal success
SeekingAlpha
AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash
SeekingAlpha
AbbVie results beat expectations despite low-cost competition to blockbuster Humira
MarketWatch
AbbVie buys Parkinson's disease drug developer Mitokinin
SeekingAlpha
FAQs
What is AbbVie stock price today?
The current price of AbbVie is 251.85 USD — it has decreased by -2.38% in the past 24 hours. Watch AbbVie stock price performance more closely on the advanced chart.
What is AbbVie stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie stocks are traded under the ticker ABBV.
Is ABBV stock price going up?
ABBV stock has decreased by -2.84% in the past week, has increased by 0.18% in the past month, and has increased by 33.24% in the past year. See more data on ABBV chart.
What is the analyst recommendation for ABBV?
As of 01 Aug 2026, out of 16 analyst recommendations, the majority rate ABBV as a buy.
What is ABBV market cap?
As of today, ABBV has the market capitalization of 465.02B USD. Explore our list of stocks ranked by market cap to compare ABBV with other stocks.
Does ABBV release financial reports?
Yes, you can track ABBV financials in yearly and quarterly reports on Profit.com.
When is ABBV next earnings date?
ABBV is going to release the next earnings report on -. Keep track of upcoming events with our Earnings Calendar.
What were ABBV Earnings for the last quarter?
ABBV reported earnings of $2.65 per share for the last quarter, lower then the estimate of $2.67 per share, resulting in a -0.75% surprise. The estimated earnings for the next quarter are $3.64 per share. See more details about ABBV earnings on Profit.com.
What was ABBV Revenue for the last quarter?
ABBV's revenue for the last quarter was 15B USD, lower then the estimated 17.3B USD. The estimated revenue for the next quarter is 16.82B USD See more stats in ABBV financial reports on Profit.com.
What was ABBV Net Income for the last quarter?
ABBV net income for the last quarter is 699M USD, while the quarter before that showed 1.82B USD of net income which accounts for -61.51% change. See more stats in ABBV financial reports on Profit.com.
Does ABBV pay dividends?
Yes, ABBV dividends are paid quarterly. The last dividend per share was 6.74. As of today, Dividend Yield (TTM)% is 2.56%.
How many employees does ABBV have?
As of 01 Aug 2026, ABBV employs approximately 57000 employees. Check out if ABBV is on our list of largest employers.
What is ABBV EBITDA?
EBITDA, which measures a company's operating performance, reflects its efficiency improvements. ABBV EBITDA is 29.92B USD, with a current EBITDA margin of 5.79%. See more stats in ABBV financial reports on Profit.com.
How to buy ABBV stocks?
Like other stocks, ABBV shares are traded on stock exchanges such as NYSE. The easiest way to buy them is through an online stock broker. Simply open an account, follow the broker's procedures, and start trading. Alternatively, you can practice trading Tesla stock on Profit.com in Playtrade Tournaments or choose a recommended broker to trade directly.
Should I invest in ABBV stock?
Investing in stocks requires thorough research, including analyzing the company’s financials, related news, and technical analysis. Currently, Tesla's technical analyst recommendations show a buy rating.